Intersect ENT, Inc. XENT
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 954.90M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -25.44
- Beta
- 1.53
- Short ratio
- 6.49
- Inst. own
- 93.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 16, 2022
- 50-d avg
- 27.83
- 200-d avg
- 27.38
- 1y target
- 28.25
News
4 years ago zacks.com
Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.
4 years ago businesswire.com
Orthofix Announces Appointment of Thomas A. West to Board of Directors
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix names Thomas A. West to the Company's Board of Directors and appoints him to the Compensation and Talent Development Committee.
4 years ago zacks.com
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?
4 years ago zacks.com
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
5 years ago zacks.com
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
5 years ago prnewswire.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class…
5 years ago prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed…
5 years ago zacks.com
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
5 years ago pulse2.com
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
Medtronic plc (NYSE:MDT) announced it entered into a definitive agreement with Intersect ENT (NASDAQ: XENT) for $1.1 billion. The post Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion…
5 years ago prnewswire.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or…
5 years ago fool.com
Why Intersect ENT Shot 12% Higher on Friday
It's official: A big peer is buying out the specialty medical device maker.
5 years ago businesswire.com
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair…
5 years ago prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic.…
5 years ago zacks.com
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
5 years ago benzinga.com
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. Medtronic's…
5 years ago businesswire.com
Intersect ENT Reports Second Quarter 2021 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported…
5 years ago prnewswire.com
Medtronic to Acquire Intersect ENT
DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with…
5 years ago benzinga.com
A Preview Of Intersect ENT's Earnings
Intersect ENT (NASDAQ:XENT) announces its next round of earnings this Friday, August 06. Here is Benzinga's everything-that-matters guide for this Friday's Q2 earnings announcement.
5 years ago zacks.com
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 years ago businesswire.com
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the…